Luke O’Neill joins Open Orphan spin-off ahead of pharma firm’s IPO
Ambitions are high for Poolbeg Pharma, which will develop drugs to fight infectious diseases
Luke O’Neill, the well-known immunologist, has joined the board of the fledgling Poolbeg Pharma which is preparing for a stock market launch in coming weeks.
Poolbeg Pharma is a newly launched spin-off of Open Orphan, the life sciences business co-founded by veteran financier Cathal Friel, and will specialise in developing drugs to treat infectious diseases.
O’Neill is a non-executive director and a member of the company’s scientific advisory board.
“Infectious disease products have now become ...